Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Nitroimidazole

Chagas Research

  • Target disease: Chagas
  • Partners (since project start)University of Auckland, New Zealand; TB Alliance, USA; Centre for Drug Candidate Optimisation (CDCO)/Monash University, Australia; Epichem, Australia; Murdoch University, Australia; Federal University of Ouro Preto (UFOP), Brazil; Institut Pasteur Korea (IPK), South Korea
  • Leadership: Head of Drug Discovery: Eric Chatelain; Project Coordinators: Delphine Launay, Stéphanie Braillard
  • Project start: April 2012
  • Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Swiss Agency for Development and Cooperation (SDC), Switzerland; Other private foundations and individuals.

  • Objective: Finalize assessment of the nitroimidazole series (TB Alliance/University of Auckland series, fexinidazole) for its potential for Chagas disease

Lead optimization activities have provided a better understanding of the essential features for a drug to be efficacious for the treatment of Chagas disease. Compounds issuing from the VL-2098 back-up programme (nitroimidazooxazine series) showing activity against T. cruzi in vitro are being further evaluated in in vivo models of Chagas disease.



Last update: September 2014


Tags: Chagas disease
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License